We’re thrilled to announce $130M in Series C funding led by @KinnevikAB and FPV, with participation from @BaillieGifford , @premjiinvest , @Lux_Capital , @trueventures , and many more new and existing partners. With this new capital, we plan to advance multiple drug candidates through Phase 1/2 clinical trials. In just 4 short years since our seed round, we’ve gone from a concept to a clinical-stage company with a deep pipeline of 10 development candidates. 🚀 Thanks to the hard work of our team and the power of our platform, we’re delivering drug candidates 4x faster than industry average—a testament to our thesis, technology, and team. This marks a significant step forward in our journey to transform the future of drug discovery. A heartfelt thank you to our investors, partners, and, most importantly, our talented team for making this possible. Here’s to the next chapter of growth, discovery, and development! 💊💡 Learn more here: Read our feature in @Bloomberg here:

#Asthma affects >250M people worldwide and has seen no new meaningful drug approvals in over a decade. Today, Enveda is announcing  that we are expanding our first-in-class lead asset, ENV-294 in asthma, along with a world-class Asthma Advisory Board. Read more here: #biotech #AI #innovation

We’re thrilled to introduce something special today… The inaugural issue of 𝗜𝗻-𝗩𝗲𝗱𝗮, a periodic collection of our thoughts and findings at the intersection of technology, science, and humanity. We believe sharing the stories, breakthroughs, and perspectives that shape our world, industry, and lives is essential. In each issue, we’ll give you a window into the advancements, bold ideas, and relentless dedication that drive us forward. In-Veda is more than just an online publication, it’s a reflection of who we are as a company, a community, and as people. Whether you’re an industry leader, partner, investor, or a passionate advocate for science and patient care, we invite you to engage with our vision and be part of this journey. Welcome to In-Veda. Read more:

This one is special… We have advanced our first drug into Phase 1 clinical trials! ENV-294 is a first-in-class small molecule with exciting potential to treat atopic dermatitis (commonly known as eczema) – an underserved and devastating inflammatory condition that impacts more than 30 million people of all ages in the US alone – and other inflammatory conditions. No one person can make a medicine, and this drug is the culmination of many brilliant and hardworking Envedians. This group of enterprising scientists, technologists, and operators has taken us from an idea to building the world's largest dataset of nature's chemistry, the most advanced AI sequencer for life’s chemical code, a state-of-the-art automated drug discovery lab, and a leading drug development team. Along with our phenomenal partners at Dr. Vince Clinical Research, we are thrilled to take this big step for Enveda and patients worldwide. This is an incredible milestone on our journey, and we are just getting started! Learn more at

Ready to push the boundaries of science? Enveda is offering two exciting challenges for the Bio x ML hackathon we're co-hosting with our friends at Lux and Evolutionary Scale! 🌐 Open to participants worldwide: More info: 👇

Exciting news! Enveda is certified as a @lovedworkplace by the @bpiworld! We're proud to be a place where employees are happiest and most satisfied at work. Thank you to our amazing team! #MostLovedWorkplace #EmployeeSatisfaction #Enveda #GreatWorkplace